The legislation includes several provisions designed to lower costs:

For the first time, the federal government would be required to negotiate prices for some of the highest-spending drugs covered under Medicare.
Drug companies would be required to pay rebates if prices rise faster than inflation for drugs used by Medicare beneficiaries.
The bill estimates 5% coinsurance for catastrophic coverage in Medicare Part D in 2024; adds a $2,000 cap on Part D out-of-pocket spending in 2025; and limits annual increases in Part D premiums from 2024 to 2030.
Monthly cost sharing for insulin products is limited to $35 for people with Medicare.
Eligibility for Medicare Pat D low-income subsidy full benefits would be expanded.
The legislation eliminates cost sharing for adult vaccines covered under Medicare Part D and improves access to adult vaccines under Medicaid and CHIP.
Finally, it would further delay implementation of the Trump administration's drug rebate rule.

These benefits would be implemented gradually in coming years:

2023 — Require drug companies to pay rebates if drug prices rise faster than inflation; limit insulin copays to $35 per month in Part D; and reduce costs and improve coverage for adult vaccines in Medicare Part D, Medicaid and CHIP.
2024 – Eliminate 5% coinsurance for Part D catastrophic coverage and expand income eligibility for Part D low-income subsidies of up to 150% of the federal poverty line.
2025 – Add $2,000 out-of-pocket cap in Part D and other drug benefit changes.
2026 – Implement negotiated prices for 10 Medicare Part D drugs.
2027– Implement negotiated prices for 15 Medicare Part D drugs.
2028 — Implement negotiated prices for 15 Medicare Part B and Part D drugs.
2029- – Implement negotiated prices for 20 Medicare Part B and Part D drugs.
2024 to 2030 –Limit Medicare Part D premium growth to no more than 6% per year

The bill would also expand the enhanced ACA subsidies, that

Instant Insights /

Health care provisions could increase access, reduce cost of Medicare